CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

FDA staff say Replimune's melanoma trial failed to prove RP1 works

Phase 3

Read the original article

Published by Endpoints News on July 28, 2026 3:05 PM

Read Original